

Application: 7240

Glytec

Page: General Information
Provide information about the company to be considered for the award. If you will be nominating an individual, specify the nominee's employer.
Name of Organization/Company Glytec
Mobile Phone Number +1 678-362-3878
Additional Contacts I do not wish to list additional contacts
Page: Entry Information
Entry Title Glytec
Category P01. Company of the Year - Healthcare Technology
Company of the Year Submission Format Written Answers
a. Briefly describe the nominated company's history and past performance (up to 200 words). Required <p>Glytec is the pioneer of insulin management software and the leader in personalized, evidence-based glycemic management solutions. Founded in 2006, Glytec developed and commercialized Glucommander®, the first FDA-cleared software-as-a-service (SaaS) platform for intravenous and subcutaneous insulin dosing. Its mission is to improve outcomes and reduce costs through safe, effective glycemic control. Glucommander is used by more than 400 hospitals and health systems nationwide and integrates seamlessly with major EHR platforms.</p> <p>With over 37 million Americans diagnosed with Type 1 or Type 2 diabetes — and many more at risk — Glytec's technology represents a major advancement in managing this widespread condition. More than one-third of hospitalized patients require insulin therapy, underscoring the need for effective software to manage care workflows — a need now emphasized by new CMS hospital glycemia reporting mandates.</p> <p>Historically, Glytec's innovations have led to reductions in severe hypoglycemia by 99.8% and overall hypoglycemia by 68%, alongside shortened length of stay and reduced readmissions. Glucommander is backed by over 100 clinical studies and whitepapers. Clients include AdventHealth, Sentara, and Novant Health, who consistently report improved safety, efficiency, and standardization through Glucommander's advanced insulin dosing and analytics capabilities.</p>
b. Outline the nominated company's achievements since the beginning of 2023 that you wish to bring to the judges' attention (up to 250 words). Required <p>Since 2023, Glytec has significantly advanced the Glucommander platform, expanding its predictive analytics, real-time decision support, and integration with top-tier EHRs. Notably, Glytec introduced enhanced real-time alerting to proactively identify patients at risk of poor glycemic outcomes, bolstering early intervention workflows. The Glucommander Metrics performance analytics dashboard was also enhanced, allowing hospitals to monitor glycemic control metrics in near real time, empowering faster quality improvement cycles.</p> <p>Glucommander's novel algorithms for subcutaneous and IV insulin dosing remain unique in the market. In 2023, Glytec reported a 78% reduction in hypoglycemia at AdventHealth using Glucommander, alongside decreases in length of stay and 30-day readmissions. Other health systems reported up to 42% faster time to glucose target and significant staff efficiency gains.</p> <p>The platform was also recognized by MedTech Breakthrough Awards as the Best Computerized Decision Support Solution for top-rated insulin management solution for customer satisfaction, with clients citing safety, ease of use, and clinical outcomes as standout features.</p> <p>Glytec expanded partnerships with EHR vendors to offer deeper integration and began deploying its new Inpatient Diabetes Quality Surveillance offering — an analytics layer that proactively flags glycemic events and supports compliance with CMS glycemic quality measures.</p> <p>These enhancements reflect Glytec's ongoing commitment to advancing insulin safety and glycemic control in a scalable, digital-first model that aligns with hospital quality, safety, and performance improvement goals.</p>

c. Explain why the achievements you have highlighted are unique or significant. If possible compare the achievements to the performance of other companies in the firm's industry and/or to the company's own past performance (up to 250 words). Required

Glucommander stands alone as the only FDA-cleared, SaaS-based insulin dosing solution that supports both IV and subcutaneous insulin management across the inpatient setting. While competitors offer insulin calculators or EHR-based pathways, they lack Glucommander's proprietary adaptive dosing algorithms, comprehensive analytics, and integration flexibility.

The performance gains achieved by Glytec clients — including a 99.8% elimination of severe hypoglycemia and consistent reductions in length of stay — are unmatched in the industry. This translates into significant clinical and financial ROI, with some clients saving up to \$1,500 per patient encounter.

Compared to traditional insulin protocols or EHR-embedded calculators, Glucommander provides automated, individualized insulin dosing recommendations, reducing nurse burden and variability in care. Its real-time surveillance and Glucommander Metrics dashboards empower clinical teams to monitor compliance and outcomes continuously — a capability largely absent in alternatives.

Glytec's impact since 2023 is especially notable in the context of rising inpatient diabetes complexity and CMS's evolving glycemic control quality measures. Its tools offer compliance-ready insights and workflow alignment with health system quality strategies.

Moreover, the system's ability to rapidly scale across hospitals — from academic medical centers to community hospitals — underscores its design maturity and operational fit. Glytec's achievements since 2023 reflect not only product innovation but clinical transformation at scale.

d. Reference any attachments of supporting materials throughout this nomination and how they provide evidence of the claims you have made in this nomination (up to 250 words). Optional

1. AdventHealth Waterman Case Study

After replacing a legacy system with Glucommander, AdventHealth Waterman reported:

An 87% reduction in delays adjusting insulin

A 54% decrease in insulin dosing errors

Over \$350,000 in annual savings

Genesis HealthCare System Case Study

Genesis implemented Glucommander to improve glycemic management outcomes across its inpatient units. Key results included:

25% reduction in mean blood glucose within 24 hours

31% fewer severe hypoglycemia events

21% increase in patients achieving target range

These improvements contributed to safer patient care and better adherence to internal quality benchmarks.

2. Karen Krofft, DNP, RN, NPD-BC, OCN, Administrative Director of Nursing Support Services at Genesis HealthCare System, states:"This upcoming CMS mandate will shed a lot o light across the country for those who don't have the ability to do what Glucommander does. It's going to be a good thing."

Aman Amin, MD
HOSPITALIST CLINICAL LEAD AND GLUCOMMANDER PHYSICIAN CHAMPION LEAD, NOVANT HEALTH notes: "By having Glucommander champions at every level of the facility, we have more of what I call an 'elbow-to-elbow' teaching opportunity, where I or the other group of champions can sit next to providers and show them in real time how we can impact patients".

3. Glytec provides a readiness guide, webinar, toolkits and compliance roadmap supporting hospitals in preparation for the 2026 CMS glycemic management quality reporting mandate.

[REDACTED FOR PUBLICATION]

Would you like to add an additional webpage link?

Yes

[Redacted]

[Redacted]

[Redacted]

[Redacted]

[Redacted]

[Redacted]

Web Page Link 7

[Redacted]

[Redacted]

[Redacted]

[Redacted]

[Redacted]

[Redacted]

[Redacted]

[Redacted]

Would you like to add an additional supporting document?

No

By your submission of this entry to The Stevie Awards, you verify that you have read and agreed to abide by the regulations, terms and conditions of the competition (<https://www.asia.stevieawards.com/rules-and-terms-conditions-competition>).

Terms and Conditions

I Agree